Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDHB | P21912 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146203 | 0.83 | PTGS2 (0.31) | — | |
| SCHEMBL1828532 | 0.82 | MAPT (0.38) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL14974284 | 0.80 | MAPT (0.42) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL15021666 | 0.77 | S1PR1 (0.42) | KDM4EPPARGPPARA | |
| SCHEMBL1831253 | 0.77 | MAPT (0.39) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2224679 | 0.77 | RAB9A (0.36) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL1828263 | 0.76 | RAB9A (0.39) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL1829407 | 0.76 | MAPT (0.38) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2225576 | 0.75 | RAB9A (0.39) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL1830757 | 0.75 | PBRM1 (0.36) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785439-B2 | 2,5,7-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8735387-B2 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-2523961-B1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-20130137685-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| EP-2583720-A1 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| EP-2318415-B1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI SA (FR) | 2013-02-20 | — | — | EP | disclosed |
| EP-2523961-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| WO-2011086075-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| EP-2318415-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010006704-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137685-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | DPYD, UNG, CDK2 | SDHB 528/4885MAPT 4602/4885MEN1 3792/4885 |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | EDNRA, OXGR1, EDF1 | SDHB 3526/4885MAPT 4276/4885MEN1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.